NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
Vaccine manufacturer employee contracts poliovirus An employee of vaccine manufacturer Bilthoven Biologicals (BBio) has been infected with a poliovirus. The virus was found in a stool sample provided by the employee. The employee concerned is now in isolation.
Incorrect emission factors used for some farms included in list of top 100 ammonia emitters At the request of the Dutch House of Representatives, RIVM compiled a list of the 100 biggest ammonia emitters in the Netherlands. Recently, the underlying data used to compile this list were disclosed pursuant to a request under the Open Government Act.
Less greenhouse gas emissions across the supply chain: survey for policy development The Dutch Climate Agreement contains measures to reduce greenhouse gas emissions in the Netherlands. Many products used in the Netherlands are manufactured abroad.
RIVM creates overview of nitrogen monitoring in water in Europe At the behest of the European Parliament, the National Institute for Public Health and the Environment (RIVM) has formulated a report on how EU member states are dealing with European regulations on nitrogen in water (nitrate). Michel Looyenstein
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.
Insufficient knowledge to protect the health of the Dutch population from climate change The climate is changing. This process is already affecting the health of people in the Netherlands. As such, it is important to take immediate action to prepare the Netherlands and its population for climate change and to reduce the effects on health